VERO Biotech is increasing its commitment to support the treatment of patients afflicted with complications of COVID-19 with GENOSYL® Delivery System (DS), the first and only FDA-approved tankless system for the delivery of inhaled nitric oxide. As a result of the first patient treated at home with GENOSYL® (nitric oxide) gas for inhalation, and the ongoing COVID-19 pandemic, VERO’s three-point response includes:
- Emergency access of GENOSYL to patients with COVID-19 complications for outpatient treatment
- Access to local Atlanta-based hospitals via Emergency Treatment Protocol (ETP)
- Significant increase in local Atlanta hiring to meet production demand for GENOSYL
Nitric oxide is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, nitric oxide targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs and is used in adult respiratory distress syndrome and persistent pulmonary hypertension of the neonate.
For more information: https://www.vero-biotech.com/vero-biotech-commits-to-atlanta-healthcare-providers-patients-and-hiring-expansions-during-covid-19-pandemic/
FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide